ARMC
LCTX icon

American Research & Management Company’s Lineage Cell Therapeutics LCTX Stock Holding History

American Research & Management Company’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,932
Closed -$5K – 375
2014
Q2 		$5K Hold
1,932
– – ﹤0.01% 337
2014
Q1 		$5K Hold
1,932
– – ﹤0.01% 334
2013
Q4 		$6K Hold
1,932
– – ﹤0.01% 330
2013
Q3 		$6K Buy
+1,932
New +$6.11K ﹤0.01% 316

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Research & Management Company's LCTX Position: Q3 2014 in Review

American Research & Management Company sold out of Lineage Cell Therapeutics (LCTX) in Q3 2014, closing a stake of 1,932 shares — an estimated $5K sold.

American Research & Management Company first reported a position in LCTX in Q3 2013 and held it in 4 quarters. The position peaked at $6K in Q4 2013. 57 funds tracked by Wall St. Rank hold LCTX as of Q3 2014.

  • American Research & Management Company reported no remaining Lineage Cell Therapeutics position as of Q3 2014 after selling out during the quarter.
  • American Research & Management Company sold 1,932 Lineage Cell Therapeutics shares in Q3 2014, an estimated $5K.
  • American Research & Management Company first reported a position in Lineage Cell Therapeutics in Q3 2013 and held it in 4 quarters.
  • American Research & Management Company's Lineage Cell Therapeutics position peaked at $6K in Q4 2013.
  • 57 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2014.

Based on American Research & Management Company's 13F filing for Q3 2014, filed 22 Oct 2014.